CARGO Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 116
- Market Cap
- $768.9M
- Website
- http://cargo-tx.com
- Introduction
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
- Conditions
- CancerRelapsed/Refractory Large B-cell Lymphoma (LBCL)
- Interventions
- Drug: firi-cel (Experimental drug)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- CARGO Therapeutics
- Target Recruit Count
- 101
- Registration Number
- NCT05972720
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCLA Division of Hematology Oncology, Los Angeles, California, United States